sorry, we can't preview this file
Rifkin_MM6_comp_effectiveness_Supplementary_material_Clean.docx (247.97 kB)
In class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma - Supplementary Material
dataset
posted on 2023-10-09, 09:17 authored by Robert M. Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter, Rafat Abonour, Hans C. Lee, Michael Stokes, Kaili Ren, Dawn Marie Stull, Dasha Cherepanov, Kimberly Bogard, Stephen J. Noga, Saulius GirniusSupplementary Figure S1. Study design and timelines
Supplementary Figure S2. Populations for the IRd and V-based cohorts Selected from US MM-6 and INSIGHT MM.
Supplementary Table S1. Patient baseline and disease characteristics before IPTW.
Supplementary Table S2. Duration of treatment with individual agents in the IRd and V-based IPTW-weighted cohorts.
Supplementary Table S3. Stem cell transplant and subsequent PI therapy in the V-based IPTW-weighted cohort.
